April 1st 2025
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 diabetes and cardiovascular disease and/or chronic kidney disease.
A look at the current landscape and how young companies can set the stage for product launch.
FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto
Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer.
Critical Shortcomings in the US' Public Health Crisis Plans
March 28th 2025Marcel Botha, CEO of 10XBeta, discusses shortcomings in the US's emergency plans for rapid innovation and manufacturing during public health crises, highlighting the need for innovation pipelines, supply chain resilience, and regulatory clarity.
Ethical Considerations for AI Use in Medication Access
March 26th 2025Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses ethical considerations surrounding AI use in medication access and how the industry can ensure that these technologies are used responsibly and equitably.